Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Novo Nordisk A/S (NVO : NYSE)

• Company Description    Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd. Number of Employees: 77,349

• Price / Volume Information    Yesterday's Closing Price: $69.82 Daily Weekly Monthly 20 Day Moving Average: 8,373,025 shares Shares Outstanding: 4,465.00 (millions) Market Capitalization: $311,746.31 (millions) Beta: 0.64 52 Week High: $143.69 52 Week Low: $57.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.54% -5.15% 12 Week 13.34% -8.88% Year To Date -18.83% -22.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Novo Alle 1 - Bagsvaerd,G7 2880 DNK ph: 45-4444-8888 fax: 45-4449-0555 investor-relations@novonordisk.com http://www.novonordisk.com

• General Corporate Information    Officers Lars Fruergaard Jorgensen - President and Chief Executive Officer Helge Lund - Chairman Henrik Poulsen - Vice chairman Karsten Munk Knudsen - Executive Vice President and Chief Financial Offic Kasim Kutay - Director Peer Information Novo Nordisk A/S (AGN.) Novo Nordisk A/S (NVS) Novo Nordisk A/S (NVO) Novo Nordisk A/S (LLY) Novo Nordisk A/S (RHHBY) Novo Nordisk A/S (JNJ) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: Large Cap Pharma Sector: Medical CUSIP: 670100205 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 4,465.00 Most Recent Split Date: 9.00 (2.00:1) Beta: 0.64 Market Capitalization: $311,746.31 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 2.35% Current Fiscal Quarter EPS Consensus Estimate: $0.99 Indicated Annual Dividend: $1.64 Current Fiscal Year EPS Consensus Estimate: $3.90 Payout Ratio: 0.48 Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: 0.14 Estmated Long-Term EPS Growth Rate: 14.41% Last Dividend Paid: 03/31/2025 - $0.82 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: 17.92 Trailing 12 Months: 20.66 PEG Ratio: 1.24 Price Ratios Price/Book: 15.95 Price/Cash Flow: 17.90 Price / Sales: 7.15 EPS Growth vs. Year Ago Period: 10.84% vs. Previous Quarter: 1.10% Sales Growth vs. Year Ago Period: 15.71% vs. Previous Quarter: -10.15% ROE 06/30/25 - - 03/31/25 - 80.94 12/31/24 - 84.68 ROA 06/30/25 - - 03/31/25 - 24.23 12/31/24 - 26.29 Current Ratio 06/30/25 - - 03/31/25 - 0.74 12/31/24 - 0.74 Quick Ratio 06/30/25 - - 03/31/25 - 0.56 12/31/24 - 0.55 Operating Margin 06/30/25 - - 03/31/25 - 34.52 12/31/24 - 34.81 Net Margin 06/30/25 - - 03/31/25 - 34.52 12/31/24 - 34.81 Pre-Tax Margin 06/30/25 - - 03/31/25 - 43.63 12/31/24 - 43.80 Book Value 06/30/25 - - 03/31/25 - 4.38 12/31/24 - 4.66 Inventory Turnover 06/30/25 - - 03/31/25 - 1.20 12/31/24 - 1.19 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.70 12/31/24 - 0.62 Debt-to-Capital 06/30/25 - - 03/31/25 - 41.01 12/31/24 - 38.46

Powered by Zacks Investment Research ©